Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entresto initiation in ADHF patients
NCT02661217Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 4, randomised, open-label trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Novartis. Primary endpoint: Percentage of Patients Achieving the Target Dose of LCZ696 200 mg Bid at 10 Weeks Post Randomization. Started Feb 2016; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02661217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661217.